AARD — Aardvark Therapeutics Balance Sheet
0.000.00%
- $277.94m
- $136.12m
- 23
- 31
- 63
- 32
Annual balance sheet for Aardvark Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|
| Period Length: | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Cash and Equivalents | |||
| Short Term Investments | |||
| Cash and Short Term Investments | 16.1 | 9.99 | 73.7 |
| Prepaid Expenses | |||
| Total Other Current Assets | |||
| Total Current Assets | 16.5 | 10.4 | 74.1 |
| Net Property, Plant And Equipment | 0.252 | 0.155 | 0.735 |
| Other Long Term Assets | |||
| Total Assets | 16.8 | 10.5 | 77.5 |
| Accounts Payable | |||
| Accrued Expenses | |||
| Notes Payable / Short Term Debt | |||
| Total Other Current Liabilities | |||
| Total Current Liabilities | 0.595 | 1.38 | 4.93 |
| Total Long Term Debt | |||
| Total Debt | |||
| Total Other Liabilities | |||
| Total Liabilities | 0.776 | 1.43 | 5.39 |
| Redeemable Preferred Stock | |||
| Non Redeemable Preferred Stock | |||
| Common Stock | |||
| Additional Paid In Capital | |||
| Retained Earnings (Accumulated Deficit) | |||
| Total Equity | 16 | 9.1 | 72.1 |
| Total Liabilities & Shareholders' Equity | 16.8 | 10.5 | 77.5 |
| Total Common Shares Outstanding | |||
| Total Preferred Shares Outstanding |